Therapeutics/Diagnostics News

WASHINGTON — Mebeverine was not superior to placebo for the treatment of pediatric irritable bowel syndrome and functional abdominal pain, although active drug labeling significantly improved treatment success, researchers reported.

WASHINGTON — Darvadstrocel demonstrated “no statistically significant or clinically meaningful” benefit vs. placebo for complex perianal fistulas and Crohn’s disease, according to ADMIRE-CD II trial data presented at Digestive Disease Week.

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.

WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis.

WASHINGTON — Survodutide sustained improvement in liver fat content, liver enzymes and fibrosis biomarkers in patients with metabolic dysfunction-associated steatohepatitis at 28 weeks, according to a late-breaking abstract presented here.

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo-controlled period through 20 weeks, according to data.

WASHINGTON — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses real-world results for Rebyota as a treatment of recurrent Clostridioides difficile infection, which were presented at Digestive Disease Week.

WASHINGTON — A blood-based screening test detected colorectal cancer with a sensitivity of 79.2% and a specificity of 91.5% among average-risk adults aged 45 to 85 years, according to research presented at Digestive Disease Week.

WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.

WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.